Combining nivolumab with chemotherapy improves survival rates and reduces side effects in advanced Hodgkin lymphoma patients.

A recent clinical trial revealed that combining the immunotherapy drug nivolumab with standard chemotherapy significantly enhances survival rates for patients with advanced Hodgkin lymphoma. The study reported a two-year progression-free survival rate of 92% for the nivolumab regimen, compared to 83% for the previous standard treatment. This new approach also presents fewer side effects, leading to hopes for its adoption as a standard treatment option.

October 16, 2024
26 Articles